New Zealand firm Ora Pharm has struck a deal to supply dried flower to Canngea for the manufacture and distribution of its medicinal cannabis products on both sides of the Tasman.
The partnership marks Ora Pharm’s launch in the Australian market with both dried flower and finished products.
It said it is developing patient-ready tincture formulations blended with native New Zealand botanicals which will be manufactured by Canngea under strict GMP processes. It is also developing unique cannabis strains exclusively for its new partner.
Founder and CEO Zoe Reece said: “Pharmaceutical-grade cannabis quality starts with the seed, and the seed we are growing our cannabis from is a unique, high-quality, high-yield strain which we expect to produce excellent results.”
Canngea is a licensed B2B contract manufacturer and wholesale distributor of GMP-certified, pharmaceutical-grade medicinal cannabis products. It has a strategic partnership with the University of Sydney to facilitate research and development.
Managing director Ryan Ballantyne said: “We’re thrilled to be partnering with Ora Pharm to develop medicinal cannabis strains exclusively for the Australian market. We have specifically chosen these strains to develop in order to meet the growing demand from patients.”
He added: “Ora Pharm’s dedication to quality and access to unique cultivars was what attracted us to working with the team across the Tasman. While we develop these exclusive strains, Canngea will be manufacturing, storing and distributing Ora Pharm’s patient-ready oral solutions for both the Australian and New Zealand markets.”
Ora Pharm recently listed on the Syndex exchange in a bid to raise NZ$11.5 million through a Series A funding round.